Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
11 studies found for:    solanezumab

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
2 Recruiting A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
3 Completed A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
Condition: Alzheimer's Disease
Intervention: Drug: solanezumab
4 Active, not recruiting Continued Safety Monitoring of Solanezumab in Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
5 Active, not recruiting Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Conditions: Alzheimers Disease;   Dementia;   Alzheimers Disease, Familial
Interventions: Drug: Gantenerumab;   Drug: Solanezumab;   Drug: Matching Placebo (Gantenerumab);   Drug: Matching Placebo (Solanezumab)
6 Completed Effect of LY2062430 on the Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430;   Drug: Placebo
7 Recruiting Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Condition: Cognition Disorders
Interventions: Drug: Solanezumab;   Drug: Placebo
8 Completed Effect of LY2062430 on the Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430;   Drug: Placebo
9 Completed Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
10 Recruiting A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Conditions: Healthy;   Alzheimer's Disease;   Mild Cognitive Impairment
Interventions: Drug: LY2599666;   Drug: Solanezumab;   Drug: Placebo SC;   Drug: Placebo IV
11 Completed Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430;   Drug: Placebo
To Top

† Indicates status has not been verified in more than two years